4.7 Article

The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome-a double-blind randomized placebo-controlled study

Journal

FERTILITY AND STERILITY
Volume 96, Issue 2, Pages 445-U521

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.fertnstert.2011.05.085

Keywords

Polycystic ovary syndrome; rosiglitazone; insulin resistance; hyperandrogenism; Chinese

Funding

  1. Lee Hysan Foundation Research Grant/Endowment Fund [2003/2004]
  2. CUHK [2041092]
  3. GlaxoSmithKline

Ask authors/readers for more resources

Objective: To investigate whether an insulin sensitizer has any effect on amenorrhea and clinical and biochemical hyperandrogenism in Chinese women with polycystic ovarian syndrome (PCOS). Design: Randomized controlled double-blind trial. Setting: A tertiary referral center, Hong Kong. Patient(s): Chinese women who fulfilled the Rotterdam criteria of PCOS (n = 70). Intervention(s): Rosiglitazone 4 mg daily for the first month followed by 4 mg twice daily for 11 months. Main Outcome Measure(s): Menstrual status as well as clinical and biochemical hyperandrogenism. Result(s): There is a significantly higher rate of regular menses among the treatment arm (16 [50.0%] of 32 vs 4 [11.8%] of 34) at 6 months and the improvement appeared to be sustained (10 [41.7%] of 24 vs 6 [20.0%] of 30) at 12 months. There was no change in the acne and hirsutism scores as well as serum T levels in both arms. Conclusion(s): We found a possible benefit in menstrual cyclicity but a lack of improvement in hyperandrogenism in our Chinese population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available